Appendix II – Supplementary Figures

**Short title:** Key Model Drivers in HF

**Economic Evaluations of Pharmacological Treatments in Heart Failure Patients: A Methodological Review with a Focus on Key Model Drivers**

Gian Luca Di Tanna (ORCID ID: 0000-0002-5470-3567)¹ · Shuxian Chen² · Anna Bychenkova³ · Heidi S. Wirtz⁴ · Karen L. Burrows⁵ · Gary Globe⁴

¹ The George Institute for Global Health, Sydney, Australia
² The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA
³ Global Health Economics, Amgen Inc, Uxbridge, UK
⁴ Global Health Economics, Amgen Inc, Thousand Oaks, CA, USA
⁵ Envision Pharma Group, Horsham, UK

[[Corresponding Author]] Gary Globe, PhD, MBA

Director, Global Health Economics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA

Email: gglube@amgen.com; Office: +1 805.447.6522
Appendix Fig. S1 PRISMA Flow diagram

*Ollendorf DA et al., 2016 was excluded from the analysis of Key Drivers as even though it met inclusion/exclusion criteria, it summarized previously published information. Polistena B et al., 2014 was not included in the CHEERS cohort as the study was published in Italian.*
Appendix Fig. S2 Overview of the quality of included publications according to the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist [1,2].

- Single study–based estimate;
- Synthesis-based estimates;
- Single study–based economic evaluation;
- Model-based economic evaluation;
- Model-based economic evaluation.

1. Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Value Health. 2012; 15(6): 843-850.
2. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013; 16(2): 231-250.